Development of a plasma- and albumin -free recombinant von Willebrand factor

Hamostaseologie

Volumn 29, Issue SUPPL1, 2009, Pages

  Turecek, P L ^a   Mitterer, A ^a   Matthiessen, H P ^a   Gritsch, H ^a   Varadi, K ^a   Siekmann, J ^a   Schnecker, K ^a   Plaimauer, B ^a   Kaliwoda, M ^a   Purtscher, M ^a   Woehrer, W ^a   Mundt, W ^a   Muchitsch, E M ^a   Suiter, T ^a   Ewenstein, B M ^a   Ehrlich, H J ^a   Schwarz, H P ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Hemophilia; Recombinant von Willebrand factor; Substitution therapy; Von Willebrand disease

Indexed keywords

ALBUMINOID; BLOOD CLOTTING FACTOR 8; RECOMBINANT PROTEIN; VON WILLEBRAND FACTOR;

ANIMAL; AREA UNDER THE CURVE; ARTICLE; CHEMISTRY; CHO CELL; CRICETULUS; DISEASE MODEL; DOG; GENETICS; HALF LIFE TIME; HAMSTER; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; MOUSE MUTANT; PLASMA; SWINE; VON WILLEBRAND DISEASE;

ALBUMINS; ANIMALS; AREA UNDER CURVE; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DOGS; FACTOR VIII; HALF-LIFE; HUMANS; MICE; MICE, KNOCKOUT; PLASMA; RECOMBINANT PROTEINS; SWINE; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 75549090170     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617202     Document Type: Article

References (31)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
2. Ofosu FA, Freedman J, Semple JW. Plassma-derived biological medicines used to promote haemostasis. Thromb Haemost 2008; 99: 851-862.
3. Franchini M, Targher G, Lippi G. Prophylaxis in von Willebrand disease. Ann Hematol 2007; 86: 699-704.
4. Gill JC. Treatment of urgent bleeding in von Willebrand disease. Thromb Res 2007; 120 (Suppl 1): S21-S25.
5. Nichols WL, Hultin MB, James AH et al. Von Willebrand disease (VWD): Evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
6. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140-1143.
7. Aihara M, Sawada Y, Ueno K et al. Visualization of von Willebrand factor multimers by immunoenzymatic stain using avidin-biotin peroxidase complex. Thromb Haemost. 1986; 55: 263-267.
8. Denis C, Methia N, Frenette PS et al. A mouse model of severe von Willebrand disease: Defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 1998; 95: 9524-9529.
9. Blanchette VS, Shapiro AD, Liesner RJ et al. rAHFPFM Clinical Study Group. Plasma and albuminfree recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-1326.
10. Turecek PL, Váradi K, Schlokat U et al. In vivo and in vitro processing of recombinant pro-von Willebrand factor. Histochem Cell Biol. 2002; 117: 123-129.
11. Turecek PL, Pichler L, Auer W et al. Evidence for extracellular processing of pro-von Willebrand factor after infusion in animals with and without severe von Willebrand disease. Blood 1999; 94: 1637-1647.
12. Schlokat U, Fischer BE, Herlitschka S et al. Production of highly homogeneous and structurally intact recombinant von Willebrand factor multimers by furin-mediated propeptide removal in vitro. Biotechnol Appl Biochem 1996; 24: 257-267.
13. Wise RJ, Dorner AJ, Krane M et al. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem 1991; 266: 21948-21955.
14. Varadi K, Rottensteiner H, Vejda S et al. Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor. J Thromb Haemost 2009; 7: 1134-1142.
15. Hubbard AR, Heath AB. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150). J Thromb Haemost 2004; 2: 1380-1384.
16. Hubbard AR. Von Willebrand factor standards for plasma and concentrate testing. Semin Thromb Hemost. 2006; 32: 522-528.
17. Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004; 10: 243-249.
18. Budde U, Metzner HJ, Müller HG. Comparative analysis and classification of von Willebrand factor/ factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost 2006; 32: 626-635.
19. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis 2005; 16 (Suppl 1): S17-S21.
20. Federici AB, Castaman G, Thompson A, Berntorp E. Von Willebrand's disease: clinical management. Haemophilia 2006; 12 (Suppl 3):152-158.
21. Parti R, Schoppmann A, Lee H, Yang L. Stability of lyophilized and reconstituted plasma/albumin-free recombinant human factor VIII (ADVATE rAHFPFM). Haemophilia 2005; 11: 492-496.
22. Shapiro AD. Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocogalpha; ADVATE) in the management of hemophilia A. Vasc Health Risk Manag 2007; 3: 555-565.
23. Fischer BE, Schlokat U, Mitterer A et al. Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co-expressing recombinant furin. FEBS Lett 1995; 375: 259-262.
24. Preininger A, Schlokat U, Mohr G et al. Strategies for recombinant Furin employment in a biotechnological process: complete target protein precursor cleavage. Cytotechnology 1999; 30: 1-16.
25. Turecek PL, Furlan M, Lämmle B et al. Cleavage of recombinant von Willebrand factor by a VWF-depolymerizing protease. Poster presented at the 38th Annual Meeting of the American Society of Hematology (ASH), Orlando, FL/USA, Dec. 6-10, 1996. Blood 1996; 88 (Suppl 1): 326a.
26. Roussi J, Turecek PL, André P et al. Effects of human recombinant, plasma-derived and porcine von Willebrand factor in pigs with severe von Willebrand disease. Blood Coagul Fibrinolysis 1998; 9: 361-372.
27. Plaimauer B, Schlokat U, Turecek PL et al. Recombinant von Willebrand factor: preclinical development. Semin Thromb Hemost 2001; 27: 395-403.
28. Schwarz HP, Dorner F, Mitterer A et al. Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. Haemophilia 1998; 4 (Suppl 3): 53-62.
29. Schwarz HP, Dorner F, Mitterer A et al. Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. Wien Klin Wochenschr 1999; 111: 181-191.
30. Turecek PL, Gritsch H, Pichler L et al. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. Blood 1997; 90: 3555-3567.
31. Schwarz HP, Schlokat U, Mitterer A et al. Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease. Semin Thromb Hemost 2002; 28: 215-226.